Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure

American Journal of Medicine

Volumn 116, Issue 7, 2004, Pages 466-473

  Aronson, Doron ^a   Mittleman, Murray A ^b   Burger, Andrew J ^b,c  

^a RAMBAM MEDICAL CENTER   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; NITROGEN; UREA;

ADULT; ARTICLE; CARDIOVASCULAR PERFORMANCE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE MARKER; EVALUATION; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY PLASMA FLOW; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CAUSE OF DEATH; CREATININE; ENDOTHELIN-1; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT ADMISSION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENIN; STATISTICS; SURVIVAL ANALYSIS;

EID: 1642296418     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.11.014     Document Type: Article

References (45)

1. Schrier R.W., Abraham W.T. Hormones and hemodynamics in heart failure. N Engl J Med. 341:1999;577-585.
2. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 82:1990;1724-1729.
3. Miller W.L., Redfield M.M., Burnett J.C. Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 83:1989;317-320.
4. Dries D.L., Exner D.V., Domanski M.J., et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 35:2000;681-689.
5. Hillege H.L., Girbes A.R., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 102:2000;203-210.
6. Mahon N.G., Blackstone E.H., Francis G.S., et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol. 40:2002;1106-1113.
7. Jong P., Vowinckel E., Liu P.P., et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure a population-based study. Arch Intern Med. 162:2002;1689-1694.
8. Jaagosild P., Dawson N.V., Thomas C., et al. Outcomes of acute exacerbation of severe congestive heart failure quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. Arch Intern Med. 158:1998;1081-1089.
9. Dzau V.J., Colucci W.S., Hollenberg N.K., Williams G.H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 63:1981;645-651.
10. Benedict C.R., Johnstone D.E., Weiner D.H., et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol. 23:1994;1410-1420.
11. Colucci W.S., Elkayam U., Horton D.P., et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 343:2000;246-253.
12. Burger A.J., Horton D.P., LeJemtel T., et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure the PRECEDENT study. Am Heart J. 144:2002;1102-1108.
13. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
14. Ajayi A.A. Estimation of creatinine clearance from serum creatinine utility of the Cockroft and Gault equation in Nigrian patients. Eur J Clin Pharmacol. 40:1991;429-431.
15. Luke D.R., Halstenson C.E., Opsahl J.A., Matzke G.R. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther. 48:1990;503-508.
16. Robert S., Zarowitz B.J., Peterson E.L., Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med. 21:1993;1487-1495.
17. Robertshaw M., Lai K.N., Swaminathan R. Prediction of creatinine clearance from plasma creatinine comparison of five formulae. Br J Clin Pharmacol. 28:1989;275-280.
18. Waller D.G., Fleming J.S., Ramsey B., Gray J. The accuracy of creatinine clearance with and without urine collection as a measure of glomerular filtration rate. Postgrad Med J. 67:1991;42-46.
19. Suzuki N., Matsumoto H., Kitada C., et al. A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods. 118:1989;245-250.
20. Manjunath G., Tighiouart H., Ibrahim H., et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 41:2003;47-55.
21. Al Suwaidi J., Reddan D.N., Williams K., et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 106:2002;974-980.
22. Dossetor J.B. Creatininemia versus uremia. The relative significance of blood urea nitrogen and serum creatinine concentrations in azotemia. Ann Intern Med. 65:1966;1287-1299.
23. Martin P.Y., Schrier R.W. Sodium and water retention in heart failure pathogenesis and treatment. Kidney Int Suppl. 59:(suppl):1997;S57-S61.
24. Packer M. The neurohormonal hypothesis a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 20:1992;248-254.
25. Cody R.J., Covit A.B., Schaer G.L., et al. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 77:1986;1441-1452.
26. Ichikawa I., Ferrone R.A., Duchin K.L., et al. Relative contribution of vasopressin and angiotensin II to the altered renal microcirculatory dynamics in two-kidney Goldblatt hypertension. Circ Res. 53:1983;592-602.
27. Kohan D.E. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 29:1997;2-26.
28. Shayakul C., Steel A., Hediger M.A. Molecular cloning and characterization of the vasopressin-regulated urea transporter of rat kidney collecting ducts. J Clin Invest. 98:1996;2580-2587.
29. Bankir L.T., Trinh-Trang-Tan M.M. Renal urea transporters. Direct and indirect regulation by vasopressin. Exp Physiol. 85:(suppl):2000;243S-252S.
30. Francis G.S., Siegel R.M., Goldsmith S.R., et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 103:1985;1-6.
31. King A.J., Brenner B.M., Anderson S. Endothelin a potent renal and systemic vasoconstrictor peptide. Am J Physiol. 256:1989;F1051-1058.
32. Badr K.F., Murray J.J., Breyer M.D., et al. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest. 83:1989;336-342.
33. Wada A., Tsutamoto T., Ohnishi M., et al. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure comparison of effects with those of endothelin A receptor antagonism. Circulation. 99:1999;570-577.
34. Rich M.W. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 45:1997;968-974.
35. Haldeman G.A., Croft J.B., Giles W.H., Rashidee A. Hospitalization of patients with heart failure National Hospital Discharge Survey, 1985 to 1995. Am Heart J. 137:1999;352-360.
36. Ghali J.K., Cooper R., Ford E. Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med. 150:1990;769-773.
37. Felker G.M., Adams K.F. Jr, Konstam M.A., et al. The problem of decompensated heart failure nomenclature, classification, and risk stratification. Am Heart J. 145:(suppl):2003;S18-S25.
38. Cuffe M.S., Califf R.M., Adams K.F. Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure a randomized controlled trial. JAMA. 287:2002;1541-1547.
39. Goldberger J.J., Peled H.B., Stroh J.A., et al. Prognostic factors in acute pulmonary edema. Arch Intern Med. 146:1986;489-493.
40. Chin M.H., Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol. 79:1997;1640-1644.
41. McDermott M.M., Feinglass J., Lee P.I., et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J. 134:1997;728-736.
42. Varadarajan P., Pai R.G. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions results from a cohort of 2,258 hospitalized patients. J Card Fail. 9:2003;107-112.
43. Kao W., Costanzo M.R. Prognosis determination in patients with advanced heart failure. J Heart Lung Transplant. 16:(suppl):1997;S2-S6.
44. Wilson J.R., Schwartz J.S., Sutton M.S., et al. Prognosis in severe heart failure relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol. 2:1983;403-410.
45. Eichhorn E. Prognosis determination in heart failure. Am J Med. 110:(suppl):2001;14S-35S.